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inﬂammatory bowel disease’ by Orlando et al
We thank Orlando et al1 for the critical appraisal of our paper.2
However, we believe that the limited sample size and the lack of
sufﬁcient follow-up do not support unmistakable evidence of
clinical beneﬁt of vedolizumab in spondyloarthritis (SpA). First
of all, merely 36 out of 53 patients with inﬂammatory bowel
disease (IBD) completed the 6-week induction phase at the last
recorded observation, which makes the interpretation of data
premature. Hence, as stated in our paper, mean time to ﬂare in
our patients was calculated at 64 days after the initiation of
vedolizumab, ranging up to 114 days in these selected cases.
The patients presented in the series from Orlando et al are also
much older (mean 51.5 years vs 36.0 years) and display a higher
rate of surgical intervention (>60%) compared with our cases,
which may respectively reﬂect a population less likely to
develop SpA features and a disturbed gastrointestinal architec-
ture in therapy-resistant patients. Similarly, no data on concomi-
tant medication, which might be synergistic, are provided.
Nevertheless, no induction or ﬂare of SpA was seen in this small
prospective cohort. This observation does not necessarily
contradict with our case series, as the prevalence of these ﬁnd-
ings in clinical practice is currently unknown and should be
further investigated.
Orlando et al do not report any induction or ﬂare of SpA in
their small prospective cohort, but go as far as suggesting a
clinical beneﬁt. However, less than half of patients of 14 active
patients with SpA experienced a response, which was vaguely
described as a ‘sharp clinical beneﬁt’ at the level of the joint.
Unfortunately, objective signs of disease activity and/or outcome
measures such as MRI inﬂammation or imaging are lacking in
the report, making the data difﬁcult to interpret. Surprisingly,
one of these six patients even responded well at the level of the
joint, in absence of a gut response. Although we cannot exclude
some efﬁcacy, taking the high placebo response in SpA in up to
20%,3 4 the follow-up time and the small sample size of this
cohort into account, precaution is needed to make ﬁrm conclu-
sions based on these results. In any case, the efﬁcacy of vedoli-
zumab in IBD-associated joint disease, if any, does not seem to
measure up to the efﬁcacy of anti-tumour necrosis factor
reported previously in over 60% in IBD-related arthritis.5 6 The
lack of mucosal vascular addressin cell adhesion molecule 1
(MADCAM-1) expression in synovial tissue despite the presence
of α4β7 on synovial T cells in SpA, which contrasts with the gut-
speciﬁc interaction with MADCAM-1, provides scientiﬁc ration-
ale for a differential response on joint versus gut symptoms.7 8
In conclusion, the overall efﬁcacy of vedolizumab in
IBD-associated SpA remains unclear. The report of Orlando
et al suggests some level of response in selected cases but the
series is not sufﬁciently powered and the follow-up is too short
in duration to permit ﬁrm conclusions on efﬁcacy in SpA. It is
clear that only placebo-controlled trials—and not cohort studies
—will be able to address the remaining questions regarding the
impact of vedolizumab in IBD-associated SpA.
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